Table 1.
Baseline patient characteristics
| Parameter | No OAC | VKA | p value | NOAC | p value | Included patients, n (%) |
|---|---|---|---|---|---|---|
| n (%) | 4867 (78.8) | 479 (7.8) | n. a | 827 (13.4) | n. a | 6173 (100) |
| Age, mean ± SD | 72.0 ± 13.5 | 77.7 ± 10.9 | < 0.005 | 77.7 ± 10.9 | < 0.005 | 6169 (99.9) |
| Female, n (%) | 2409 (49.5) | 252 (52.6) | 0.11 | 469 (57.8) | < 0.005 | 6170 (100) |
| Antiplatelet therapy, n (%) | 1819 (37.4) | 27 (5.6) | < 0.005 | 78 (9.4) | < 0.005 | 6173 (100) |
| Arterial hypertension, n (%) | 3632 (75.3) | 419 (88.4) | < 0.005 | 703 (86.4) | < 0.005 | 6112 (99.0) |
| Diabetes mellitus, n (%) | 998 (20.7) | 119 (25.2) | 0.05 | 231 (28.4) | < 0.005 | 6107 (98.9) |
| Hyperlipidemia, n (%) | 1823 (37.9) | 228 (48.4) | < 0.005 | 368 (45.5) | < 0.005 | 6093 (98.7) |
| Atrial fibrillation, n (%) | 1438 (29.9) | 413 (86.9) | < 0.005 | 715 (87.5) | < 0.005 | 6107 (98.9) |
| History of smoking, n (%) | 1208 (27.3) | 72 (17.5) | < 0.005 | 144 (19.4) | < 0.005 | 5568 (90.2) |
| pmRS, median (min, max; interquartile range) | 0 (0, 5; 1) | 0 (0, 5; 2) | < 0.005 | 0 (0, 5; 2) | < 0.005 | 6005 (97.3) |
OAC oral anticoagulation, VKA vitamin K antagonist, NOAC non-vitamin K antagonist oral anticoagulant, pmRS premorbid modified Rankin scale